Molecular structure of CI 994, CAS Number: 112522-64-2
CI 994 (CAS 112522-64-2)
See product citations (1)
Alternate Names:
Acetyldinaline, Tacedinaline; N-acetyldinaline
Application:
CI 994 is an HDAC1, HDAC3, HDAC6, and HDAC8 inhibitor
CAS Number:
112522-64-2
Purity:
≥98%
Molecular Weight:
269.3
Molecular Formula:
C15H15N3O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CI 994 is an HDAC (histone deacetylase) inhibitor for HDAC1 (Ki = 0.41 μM), HDAC3 (Ki = 0.75 μM), HDAC6 (Ki >100 μM), and HDAC8 (Ki >100 μM). CI 994 is an inhibitor of HDAC2. It induces apoptosis and mediates G1 cell cycle arrest.
CI 994 (CAS 112522-64-2) References
- Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. | Kraker, AJ., et al. 2003. Mol Cancer Ther. 2: 401-8. PMID: 12700284
- Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. | Beckers, T., et al. 2007. Int J Cancer. 121: 1138-48. PMID: 17455259
- CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. | Hubeek, I., et al. 2008. Oncol Rep. 19: 1517-23. PMID: 18497959
- Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-κB and the downstream c-Fos/NFATc1 signaling pathways. | Guo, D., et al. 2019. Eur J Pharmacol. 848: 96-104. PMID: 30682334
- Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT). | Kim, HY., et al. 2021. Front Oncol. 11: 648023. PMID: 34367950
- Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A. | Lin, HY., et al. 2022. Biomed Pharmacother. 145: 112431. PMID: 34798471
- The HDAC inhibitor CI-994 acts as a molecular memory aid by facilitating synaptic and intracellular communication after learning. | Burns, AM., et al. 2022. Proc Natl Acad Sci U S A. 119: e2116797119. PMID: 35613054
- Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. | Marquardt, V., et al. 2023. J Immunother Cancer. 11: PMID: 36639156
- Preclinical antitumor activity of CI-994. | LoRusso, PM., et al. 1996. Invest New Drugs. 14: 349-56. PMID: 9157069
- Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). | Foster, BJ., et al. 1997. Invest New Drugs. 15: 187-94. PMID: 9387041
Inhibitor of:
ASXL3, CECR2, CPA6, DNHD1, DNHD2, Dpy30, EZI, FAM120AOS, GAS41, GATAD (GATA zinc finger domain containing), GATAD2A, H2-A, HDA1, HDA4, HDA5, HDAC1, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, Histone B, Histone cluster 1 H4L, Histone cluster 2 H2AA3, Histone cluster 3 H3, Histone H3, JAZF1, LOC665622, LPPR2, MAGE-B1, MAGE-B18, mage-k1, Mammaglobin A, MetAP-1, MIER1, mSin3A9, Msx-3, MTF-2, Mxi 1, Npcd, NWD1, OTTMUSG00000016789, OTTMUSG00000016790, OTTMUSG00000016887, OTTMUSG00000018888, p130 Cas, PAGE-2, pan-Acetyl, PCDHB13, PHF12, PLAC4, RP23-480B19.10, SAP 30L, SDS3, SNF2L, STAMP2, TOX3, ZMYM6NB, ZNF673, and ZNF821.Activator of:
2900008C10Rik, ASCL2, ATF-7IP, CHRAC15, Histone cluster 1 H2A, Histone cluster 1 H2B, Histone H2A.V, Histone H2B, MORF4L1, SPT16, Swi3, and ZNF828.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CI 994, 10 mg | sc-205245 | 10 mg | $99.00 | |||
CI 994, 50 mg | sc-205245A | 50 mg | $536.00 |